Advicept - Company finances
|
EUR
|
2022
From: 2022-04-21
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | 147,337 | 270,810 | 296,826 | 297,271 |
| Profit before tax | 87,119 | 183,284 | 193,816 | 156,429 |
| Net profit | 87,119 | 174,172 | 184,116 | 147,927 |
| Equity | 87,219 | 261,391 | 365,508 | 529,585 |
| Liabilities | 7,977 | 17,501 | 16,628 | 7,267 |
| Non-current assets | 726 | 35,532 | 47,513 | 43,511 |
| Current assets | 94,470 | 242,709 | 333,858 | 493,341 |
| Total assets | 95,196 | 278,241 | 381,371 | 536,852 |
|
Taxes paid
|
||||
| STI taxes | - | 34,823 | 61,846 | 52,482 |
|
Financial indicators
|
||||
| Revenue change y/y | - | +83.8% | +9.6% | +0.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 91.5% | 62.6% | 48.3% | 27.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 99.9% | 66.6% | 50.4% | 27.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 59.1% | 64.3% | 62.0% | 49.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 59.1% | 67.7% | 65.3% | 52.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.1 | 0.0 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Advicept - Social security debts
The company had no debts to Sodra
Advicept - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-04-16 | 2026-04-20 | 60.97 |
| 2026-04-14 | 2026-04-15 | 910.85 |
| 2026-04-11 | 2026-04-13 | 849.88 |
| 2026-02-07 | 2026-02-21 | 0.04 |
| 2026-02-03 | 2026-02-06 | 33.81 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Advicept, MB (code 306067215) is a Small partnership engaged in legal activities. In 2025, the company generated revenue of €297.3K, broadly unchanged from €296.8K in 2024, after rising from €270.8K in 2023. Net profit reached €147.9K in 2025, below the €184.1K achieved in 2024 but still higher than the €174.2K reported in 2023. This points to stable turnover over the latest two years, alongside a softer profitability profile in 2025. The 2025 profit margin was 49.8%, compared with 62.0% in 2024 and 64.3% in 2023. The balance sheet strengthened further in 2025: total assets increased to €536.9K, equity rose to €529.6K, and liabilities declined to €7.3K. The equity ratio remained very high at 98.7%, while debt-to-equity was 0.01. Profitability ratios were strong, with ROE at 27.9% and ROA at 27.6%. Asset turnover stood at 0.55x, indicating moderate use of assets to generate revenue.